生物医学工程学杂志

生物医学工程学杂志

姜黄素/聚(α-氰基丙烯酸异丁酯)载药微球的制备及其药物释放

查看全文

以 α-氰基丙烯酸异丁酯(iBCA)为原料、泊洛沙姆 188 为乳化剂,以捏合法制得的姜黄素(Cur)/羟丙基-β-环糊精(HP-β-CD)包合物(Cur-HP-β-CD)为负载药物,经一步乳化法制得姜黄素/聚(α-氰基丙烯酸异丁酯)载药微球(Cur-HP-β-CD-PiBCA)。考察乳化剂、负载药物的浓度对微球粒径与分布、微球载药率及包封率的影响,并对载药微球的药物释放进行了研究。结果表明:随着乳化剂浓度从 0.01% 增加到 0.07%,载药微球粒径下降,粒径分布变宽,载药率和包封率均增加,适宜的乳化剂浓度为 0.05%;随着药物浓度从 0.03% 增加到 0.07%,微球载药率升高,包封率下降;载药微球的载药率越高,最终的药物累积释放百分率越低。姜黄素经包合和负载,不仅可以有效改善其亲水性,而且可以提高其溶出度,为提高姜黄素的生物利用度奠定了基础。

Curcumin-loaded poly (α-isobutyl cyanoacrylate) microspheres (Cur-HP-β-CD-PiBCA) were prepared by one-step emulsification with α-isobutyl cyanoacrylate as materials, poloxamer 188 as emulsifier, and curcumin complex with hydroxypropyl-β-cyclodextrin (Cur-HP-β-CD) as drug prepared by kneading method. Effects of emulsifier and drug concentration on microspheres size and distribution, drug loading and encapsulation efficiency were investigated in detail. And the curcumin release of drug-loaded microspheres was also studied. Results showed that as the emulsifier concentration increased from 0.01% to 0.07%, particle size of the drug-loaded microspheres decreased while particle size distribution, drug loading and entrapment efficiency increased. The optimized concentration of surfactant was 0.05%. With increasing the concentration of drug from 0.03% to 0.07%, drug loading of Cur-HP-β-CD-PiBCA increased, but encapsulation efficiency decreased. Additionally, the results of drug release experiments revealed that the higher drug loading of Cur-HP-β-CD-PiBCA was, the lower cumulative release percentage was. Drug-loading of cumulative inclusions in HP-β-CD by PiBCA can improve its wettability, and increase the degree of dissolution and bioavailability.

关键词: 姜黄素; α-氰基丙烯酸异丁酯; 载药微球; 药物释放

Key words: curcumin; α-isobutyl cyanoacrylate; drug-loaded microspheres; drug release

引用本文: 石淑先, 李庆钊, 陈晓农, 夏宇正. 姜黄素/聚(α-氰基丙烯酸异丁酯)载药微球的制备及其药物释放. 生物医学工程学杂志, 2018, 35(5): 749-753. doi: 10.7507/1001-5515.201701045 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. 林琳, 王平, 尹如铁, 等. 姜黄素抗肿瘤机制研究进展. 华西医学, 2009, 24(5): 1320-1322.
2. 韩刚, 霍文, 李秋影. 姜黄素的稳定性研究. 中成药, 2007, 29(2): 291-293.
3. 杨鹏波, 张华. 脂质体的研究新进展. 浙江中医药大学学报, 2013, 37(7): 936-939.
4. 张盛伟, 李湘洲, 李文生, 等. 姜黄素纳米混悬剂的制备及其表征. 林产化学与工业, 2016, 36(2): 109-114.
5. Liu Jieying, Chen Siyuan, Lv Li, et al. Recent progress in studying curcumin and its nano-preparations for cancer therapy. Curr Pharm Des, 2013, 19(11): 1974-1993.
6. Duan Jinghua, Zhang Yangde, Han Shiwei, et al. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm, 2010, 400(1/2): 211-220.
7. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci, 2009, 37(3/4): 395-404.
8. Hani U, Shivakumar H G, Srivastava A, et al. Design and optimization of curcumin-HPβCD bioadhesive vaginal tablets by 23 factorial design: in vitro and in vivo evaluation. J Pharm Innov, 2015, 10(1): 21-35.
9. Doppalapudi S, Jain A, Khan W, et al. Biodegradable polymers—an overview. Polym Adv Technol, 2014, 25(5, SI): 427-435.
10. Ćurić A, Keller B L, Reul R A, et al. Development and lyophilization of itraconazole loaded poly(butyl cyanoacrylate) nanospheres as a drug delivery system. Eur J Pharm Sci, 2015, 78(14): 121-131.
11. Tian Xinhua, Lin Xiaoning, Wei Feng, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine, 2011, 6(6): 445-452.
12. 张强, 廖工铁. 硫酸庆大霉素聚氰基丙烯酸正丁酯毫微球制备工艺研究. 中国药学杂志, 1996, 31(1): 24-27.
13. Maskarinec S A, Hannig J, Lee R C, et al. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys J, 2002, 82(3): 1453-1459.
14. Mitra A, Lin Senshang. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol, 2003, 55(7): 895-902.
15. Illum L, Khan M, Mak E. Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles. Int J Pharm, 1986, 30(1): 17-28.